Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Propranolol with Ipilimumab and Nivolumab in Advanced Melanoma
NCT05968690Phase 1Recruiting
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of naltrexone and propranolol in melanoma (4 cohorts). Primary endpoints: Safety as assessed by CTCAE v5.0 at 2 years, Dose-limiting toxicity at 28 days and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
naltrexonepropranolol
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05968690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968690.